Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Invested Capital (2016 - 2025)

Ligand Pharmaceuticals' Invested Capital history spans 16 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Invested Capital rose 22.49% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, up 22.49%, while the annual FY2025 figure was $1.0 billion, 22.49% up from the prior year.
  • Invested Capital for Q4 2025 was $1.0 billion at Ligand Pharmaceuticals, up from $950.2 million in the prior quarter.
  • Across five years, Invested Capital topped out at $1.0 billion in Q4 2025 and bottomed at $664.9 million in Q2 2023.
  • The 5-year median for Invested Capital is $801.1 million (2024), against an average of $802.2 million.
  • The largest annual shift saw Invested Capital fell 27.52% in 2023 before it rose 25.94% in 2024.
  • A 5-year view of Invested Capital shows it stood at $821.2 million in 2021, then decreased by 17.9% to $674.2 million in 2022, then increased by 3.97% to $700.9 million in 2023, then rose by 18.48% to $830.4 million in 2024, then grew by 22.49% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for LGND's Invested Capital are $1.0 billion (Q4 2025), $950.2 million (Q3 2025), and $827.3 million (Q2 2025).